id,agency_id,docket_id,title,document_type,subtype,posted_date,posted_year,posted_month,comment_start_date,comment_end_date,last_modified,fr_doc_num,open_for_comment,withdrawn,object_id
FDA-2019-E-3278-0008,FDA,FDA-2019-E-3278,Determination of Regulatory Review Period for Purposes of Patent Extension; DELSTRIGO—New Drug Application 210807,Notice,Determinations,2023-08-04T04:00:00Z,2023,8,2023-08-04T04:00:00Z,2023-10-04T03:59:59Z,2023-08-04T15:49:29Z,2023-16606,0,0,0900006485dc5b38
FDA-2019-E-3278-0007,FDA,FDA-2019-E-3278,"Determination of Regulatory Review Period for Purposes of Patent Extension; PIFELTRO—New Drug
Application 210806",Notice,Determinations,2023-08-04T04:00:00Z,2023,8,2023-08-04T04:00:00Z,2023-10-04T03:59:59Z,2023-08-04T15:49:17Z,2023-16607,0,0,0900006485dbe4a8
FDA-2019-E-3278-0005,FDA,FDA-2019-E-3278,Letter from FDA CDER to U.S. Patent and Trademark Office,Other,Letter(s),2023-07-14T04:00:00Z,2023,7,2023-07-14T04:00:00Z,,2023-07-14T18:55:02Z,,0,0,0900006485cb38f4
FDA-2019-E-3278-0006,FDA,FDA-2019-E-3278,Letter from FDA CDER to U.S. Patent and Trademark Office,Other,Letter(s),2023-07-14T04:00:00Z,2023,7,2023-07-14T04:00:00Z,,2023-07-14T21:16:05Z,,0,0,0900006485cb551c